The findings from this study further define the spectrum and frequency of germline BRCA1/BRCA2 mutations in women with ovarian cancer not selected for family history of cancer and could further inform the development of mutation-screening policies for French Canadians in Quebec. This evidence concerns the gene BRCA1 and ovarian cancer.